AMILI is a Singapore precision gut microbiome company founded in 2019 that builds a multi-ethnic repository of microbiome data and samples, including the only existing microbiome bank in Southeast Asia. Its core products include diagnostics, predictive algorithms and microbiome-modifying interventions powered by its proprietary analytics engine, AMILI Prime. The company licenses its database to academic institutions, biotech firms and food manufacturers to identify biomarkers and inform product formulation. AMILI also provides faecal microbiota transplants and has launched a consumer health brand, BIO & ME, offering probiotics and diagnostic tests based on its database, with planned rollouts in Southeast Asia and Hong Kong later this year. It focuses clinical research on health and wellness, oncology, and response to microbiome-based therapeutics, having conducted over 20 research studies valued at over $40 million. The company intends to use new funding to expand in Southeast Asia and the rest of Asia, pursue additional research partnerships, and further develop AMILI Prime.

Total raised

$11M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2022